Compare CTW & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTW | IMUX |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Japan | United States |
| Employees | N/A | 66 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 155.8M |
| IPO Year | 2025 | 2013 |
| Metric | CTW | IMUX |
|---|---|---|
| Price | $1.75 | $7.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $43.09 |
| AVG Volume (30 Days) | 13.8K | ★ 382.7K |
| Earning Date | 10-15-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $0.51 |
| 52 Week High | $3.14 | $17.43 |
| Indicator | CTW | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 36.21 |
| Support Level | $1.19 | $6.35 |
| Resistance Level | $1.88 | $8.60 |
| Average True Range (ATR) | 0.32 | 0.65 |
| MACD | -0.02 | 0.19 |
| Stochastic Oscillator | 5.48 | 46.67 |
CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.